EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety Profile and Adverse Events Associated with Motesanib in Non-squamous Non-small-cell Lung Cancer

Arib Shafiq Chaudhry, Hafiz Shahbaz Zahoor, Muhammad Ali, Hafiz Abdullah, Syed Umer Osman, Muhammad Abdullah Masood, Muhammad Saqib Haneef, Muhammad Abdul Muqtadir Qureshi, Abdul Wasay Aqeel, Huzaifa Zeeshan, Abdul Ahad Waseem, Muhammad Hamza Tariq und 1 weitere

Journal of Current Oncology · 2025-12 · 8 (2) · 86-99

DOI: 10.1177/25898892261446599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Current Oncology, online erschienen am 02.06.2026. Verfasst von Arib Shafiq Chaudhry und 12 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non-small cell lung cancer (NSCLC) remains a major contributor to cancer-related deaths, with chemotherapy offering limited survival gains. Motesanib, a multi-targeted angiogenesis inhibitor, was studied in combination with carboplatin and paclitaxel (C/P) for NSCLC therapy. Nonetheless, inconsistent efficacy outcomes and notable side effects resulted in its withdrawal. This meta-analysis investigates the tolerability of motesanib + C/P versus placebo or bevacizumab in NSCLC patients.

Objectives

To determine the safety profile of motesanib + C/P in NSCLC, with a focus on adverse events (AEs) associated with treatment.

Methods

Relevant studies were sought by conducting searches in databases such as PubMed, Cochrane, Scopus, Google Scholar, and clinicaltrials.gov. Four randomized controlled trials (RCTs) were carried out with a total of 1,945 participants. Cochrane tools were used to assess bias, and statistical evaluation was conducted using RevMan 5.3.

Results

Motesanib did not significantly improve OS or PFS compared to placebo. However, it showed a higher likelihood of hypertension (RR = 3.41, 95% CI [2.74-4.24]), gallbladder toxicity (RR = 14.04, 95% CI [3.80-51.93]), diarrhea (RR = 2.33, 95% CI [1.95-2.78]), vomiting (RR = 1.34, 95% CI [1.15-1.55]), weight loss (RR = 2.22, 95% CI [1.73-2.85]), dehydration (RR = 2.97, 95% CI [1.60-5.51]), as well as proteinuria (RR = 3.10, 95% CI [1.56-6.14]).

Conclusions

Motesanib does not provide a survival advantage over standard treatments and poses significant safety concerns, particularly regarding cardiovascular and gastrointestinal toxicity. These findings emphasize the need for cautious clinical use and further research into safer angiogenesis inhibitors for NSCLC. The findings are based on a limited number of RCTs (four studies), which should be considered when interpreting the results.

Zitieren

APA

Chaudhry, A. S., Zahoor, H. S., Ali, M., Abdullah, H., Osman, S. U., Masood, M. A., Haneef, M. S., Qureshi, M. A. M., Aqeel, A. W., Zeeshan, H., Waseem, A. A., Tariq, M. H., & Ahmed, S. (2025). Safety Profile and Adverse Events Associated with Motesanib in Non-squamous Non-small-cell Lung Cancer. Journal of Current Oncology, 8(2), 86-99. https://doi.org/10.1177/25898892261446599

Vancouver

Chaudhry AS, Zahoor HS, Ali M, Abdullah H, Osman SU, Masood MA, et al. Safety Profile and Adverse Events Associated with Motesanib in Non-squamous Non-small-cell Lung Cancer. Journal of Current Oncology. 2025;8(2):86-99. doi:10.1177/25898892261446599

BibTeX
@article{Chaudhry2025,
  author = {Chaudhry, Arib Shafiq and Zahoor, Hafiz Shahbaz and Ali, Muhammad and Abdullah, Hafiz and Osman, Syed Umer and Masood, Muhammad Abdullah and Haneef, Muhammad Saqib and Qureshi, Muhammad Abdul Muqtadir and Aqeel, Abdul Wasay and Zeeshan, Huzaifa and Waseem, Abdul Ahad and Tariq, Muhammad Hamza and Ahmed, Saad},
  title = {Safety Profile and Adverse Events Associated with Motesanib in Non-squamous Non-small-cell Lung Cancer},
  journal = {Journal of Current Oncology},
  year = {2025},
  volume = {8},
  number = {2},
  pages = {86--99},
  doi = {10.1177/25898892261446599}
}
Kostenlos starten →